ArticleCell reports2013
Regulation of telomerase alternative splicing: a target for chemotherapy.
Article in Cell reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- XRCC1 is linked to poor prognosis in adenocarcinoma of the esophagogastric junction after radiotherapy: transcriptome and alternative splicing events analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Article
- Intronic Cis-Element DR8 in hTERT Is Bound by Splicing Factor SF3B4 and Regulates hTERT Splicing in Non-Small Cell Lung Cancer.Molecular cancer research : MCR · 2022Article
- Article
- Acute Exercise Regulates hTERT Gene Expression and Alternative Splicing in the hTERT-BAC Transgenic Mouse Model.Medicine and science in sports and exercise · 2022Article
- Alternative Splicing of Human Telomerase Reverse Transcriptase (hTERT) and Its Implications in Physiological and Pathological Processes.Biomedicines · 2021Review
- Article
- RBM10 regulates human TERT gene splicing and inhibits pancreatic cancer progression.American journal of cancer research · 2021Article
- Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.Thyroid : official journal of the American Thyroid Association · 2020Article
- Review
- Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.Frontiers in endocrinology · 2020Review
- Expression and regulation of telomerase in human T cell differentiation, activation, aging and diseases.Cellular immunology · 2019Review
- Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.Genes, chromosomes & cancer · 2019Article
- Engineering a humanized telomerase reverse transcriptase gene in mouse embryonic stem cells.Scientific reports · 2019Article
- Diverse regulatory manners of human telomerase reverse transcriptase.Cell communication and signaling : CCS · 2019Review
- Insights into Telomerase/hTERT Alternative Splicing Regulation Using Bioinformatics and Network Analysis in Cancer.Cancers · 2019Review
- NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer.Nature communications · 2018Article
- Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461.Journal of experimental & clinical cancer research : CR · 2018Article
- A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy.Human molecular genetics · 2017Article
- The protein subunit of telomerase displays patterns of dynamic evolution and conservation across different metazoan taxa.BMC evolutionary biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Telomerase is present in human cancer cells but absent in most somatic tissues. The messenger RNA of human telomerase (hTERT) is alternatively spliced into mostly nonfunctional products. We sought to understand splicing so that we could decrease functional splice isoforms to reduce telomerase activity in order to complement direct enzyme inhibition. Unexpectedly, minigenes containing hTERT exons 5-10 flanked by 150-300 bp intronic sequences did not produce alternative splicing. A 1.1 kb region of 38 bp repeats ~2 kb from the exon 6/intron junction restored the exclusion of exons 7 and 8. An element within intron 8, also >1 kb from intron/exon junctions, modulated this effect. Transducing an oligonucleotide complementary to this second element increased nonfunctional hTERT messenger RNA from endogenous telomerase. These results demonstrate the potential of manipulating hTERT splicing for both chemotherapy and regenerative medicine and provide specific sequences deep within introns that regulate alternative splicing in mammalian cells by mechanisms other than the introduction of cryptic splice sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.